Lambert M. SurhoneISBN: 978-6-1320-0554-0;
s product pipeline is based on recombinant lactoferrin and lysozyme for use in medical foods, bioprocessing, cell culture and as a topical anti-infective. These proteins show promise as a supplement to oral rehydration therapy and to treat C.difficile infection because they inhibit C.difficile, but promote the growth of healthy gut flora. Ventria invites other researchers to have access to its recombinant human lactoferrin and recombinant human lysozyme through a program called BioShare. The Company has operations in Kansas, North Carolina, California and Colorado. The Company recently completed construction of a bioprocessing facility in Kansas.
- OZON.ru 1665